LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Status:
RECRUITING
Trial end date:
2026-07-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether the combination is effective in shrinking or preventing growth of prostate cancer.
The names of the study drugs used in this research study are:
* Carboplatin (A type of chemotherapy)
* 177Lu-PSMA-617 (A type of radioligand therapy)